Human G protein-coupled receptor and modulators thereof for the treatment of cell death-related disorders
| Title: | Human G protein-coupled receptor and modulators thereof for the treatment of cell death-related disorders |
|---|---|
| Patent Number: | 7,776,558 |
| Publication Date: | August 17, 2010 |
| Appl. No: | 10/549228 |
| Application Filed: | March 15, 2004 |
| Abstract: | The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In certain embodiments, the GPCR is human. In certain embodiments, the GPCR is expressed endogenously by neuronal cells or muscle cells. In certain embodiments, the GPCR is neuroprotective or myoprotective. In certain embodiments, the GPCR is a Humanin receptor. The present invention also relates to methods of using a modulator of the GPCR. A preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of neurodegenerative diseases in general, including Alzheimer's disease, Parkinson's disease, prion-associated disease, stroke and motor-neuron disease in particular, peripheral neuropathy, cerebral amyloid beta-protein angiopathy, and ischemic heart disease, including myocardial infarction and congestive heart failure. |
| Inventors: | Villegas, Sonia (San Diego, CA, US); Kelner, Gregory S. (San Diego, CA, US); Unett, David J. (San Diego, CA, US); Gatlin, Joel (San Diego, CA, US) |
| Assignees: | Arena Pharmaceuticals, Inc. (San Diego, CA, US) |
| Claim: | 1. A method comprising: (a) contacting a candidate compound with a G protein-coupled receptor (GPCR) comprising an amino acid sequence having at least 90% identity to SEQ ID NO:2, wherein said GPCR is present on a cell or isolated membrane thereof; (b) determining the ability of the compound to inhibit or stimulate the GPCR; and (c) determining if said compound modulates neuronal cell death. |
| Claim: | 2. The method of claim 1 , wherein said determining element (c) comprises contacting said compound with a neuron and determining if said compound modulates serum deprivation-induced neuronal cell death, Aβ-induced neuronal cell death or hypoxia/reoxygenation-induced neuronal cell death. |
| Claim: | 3. The method of claim 1 , wherein element (c) comprises administering said compound to a mammal. |
| Claim: | 4. The method of claim 3 , wherein element (c) comprises assaying said mammal for an effect on learning or memory. |
| Claim: | 5. The method of claim 3 , wherein element (c) comprises assaying said compound for a neuroprotective activity. |
| Claim: | 6. The method of claim 3 , wherein said mammal has a neuronal disorder. |
| Claim: | 7. The method of claim 1 , wherein said determining element (b) comprises measuring a second messenger. |
| Claim: | 8. The method of claim 1 , wherein said determining element (b) comprises measuring expression of a reporter. |
| Claim: | 9. The method of claim 1 , wherein said GPCR comprises an amino acid sequence having at least 95% identity to SEQ ID NO:2. |
| Claim: | 10. The method of claim 1 , wherein said GPCR is recombinant. |
| Claim: | 11. The method of claim 1 , wherein said GPCR binds Humanin. |
| Claim: | 12. The method of claim 1 , further comprising admixing said compound with a pharmaceutically acceptable carrier to produce a pharmaceutical composition. |
| Claim: | 13. The method of claim 12 , wherein said method further comprises administering said pharmaceutical composition to a mammal having a neuronal disorder. |
| Claim: | 14. A method comprising: (a) contacting a compound with a G protein-coupled receptor comprising an amino acid sequence having at least 90% identity to SEQ ID NO:2, wherein said G protein-coupled receptor is present on a cell or isolated membrane thereof; (b) determining the ability of the compound to bind to said G protein-coupled receptor; and (c) determining if said compound modulates neuronal cell death. |
| Claim: | 15. A method comprising: (a) contacting a candidate compound with a G protein-coupled receptor (GPCR) comprising an amino acid sequence having at least 90% identical to SEQ ID NO:2, wherein said GPCR is present on a cell or isolated membrane thereof; (b) determining the ability of the compound to inhibit or stimulate the GPCR; and (c) determining if said compound modulates muscle cell death. |
| Current U.S. Class: | 435/721 |
| Patent References Cited: | 1514930 March 2005 WO 02/068600 September 2002 WO 03/046205 June 2003 WO 03/080098 October 2003 WO 03/106683 December 2003 WO 2004/008141 January 2004 |
| Other References: | Hashimoto et al. Involvement of Tyrosine Kinases and STAT3 in Humanin-mediated neuroprotection, Oct. 28, 2005, Life Sciences vol. 77(24):3092-3104. cited by examiner Migeotte et al. Formyl Peptide Receptors: A Promiscuous Subfamily of G protein-coupled Receptors Controlling Immune Response, Dec. 2006, Cytokine & Growth Factor Reviews vol. 17(6):501-519. cited by examiner Betten A et al: “A proinflammatory peptide from Heliobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis”, J Clin Invest (2001) 108:1221-1228. cited by other Christophe T et al: “The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 . . . ”, J Biol Chem (2001) 276:21585-21593. cited by other Hashimoto Y et al: “A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes . . . ”, Proc Natl Acad Sci U S A (2001) 98:6336-6341. cited by other Kariya A et al: “Humanin accelerates the transcription of . . . ”, 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL, Nov. 2-7, 2002, Abstract No. 786.2. cited by other Ying GG et al: “Humanin, a newly identified neuroprotective factor, uses the G-protein coupled . . . ”, J Interferon Cytokine Res (2002) 22(Suppl 1):S-180, Abstract No. P-17-10. cited by other Ernst S et al: “An annexin 1 N-terminal peptide activates leukocytes by triggering different members of the formyl peptide receptor family”, J Immunol (2004) 172:7669-7676. cited by other Database WPI, Section Ch, Week 200411, Derwent Publications Ltd., London, GB; AN 2004-108321, XP002291796, (2004). cited by other Database WPI, Section Ch, Week 200414, Derwent Publications Ltd., London, GB; AN 2004-143116, XP002291797, (2002). cited by other Hashimoto Y et al: “Mechanisms of neuroprotection by a novel rescue factor humanin from Swedish mutant amyloid precursor . . . ”, Biochem Biophys Res Commun (2001) 283:460-468. cited by other Akal-Strader et al., Residues in the first extracellular loop of a G protein-coupled receptor play a role in signal transduction. J Biol Chem. 2002 277:30581-90. cited by other Bai et al., “Structure and function of the extracellular calcium-sensing receptor,” Int J Mol Med. 1999 4:115-25 (Review). cited by other Califano, “SPLASH: structural pattern localization analysis by sequential histograms,”Bioinformatics. 2000 16:341-57. cited by other Chollet et al., “Biophysical approaches to G protein-coupled receptors: structure, function and dynamics” J Comput Aided Mol Des. 1999 13:209-19 (Review). cited by other Chung Da et al., “Mutagenesis and peptide analysis of the DRY motif in the alpha2A adrenergic receptor: evidence for alternate mechanisms in G protein-coupled receptor” Biochem Biophys Res Commun. 2002 293:1233-41. cited by other Filizola et al., “BUNDLE: a program for building the transmembrane domains of G-protein-coupled receptors,” J Comput Aided Mol Des. 1998 12:111-8. cited by other Gimpl et al., “The oxytocin receptor system: structure, function, and regulation,” Physiol Rev. 2001 81:629-83 (Review). cited by other Gouldson et al., “Domain swapping in G-protein coupled receptor dimmers,” Protein Eng. 1998 11:1181-93. cited by other Gouldson et al., “Dimerization and domain swapping in G-protein-coupled receptors: a computational study,” Neuropsychopharmacology. 2000 23:S60-77. cited by other Hurley et al., “Structure-function studies of the eighth hydrophobic domain of a serotonin receptor” J Neurochem. 1999 72:413-21. cited by other Krasnoperov et al., “Structural requirements for alpha-latrotoxin binding and alpha-latrotoxin-stimulated secretion. A study with calcium-independent receptor of alpha-latrotoxin (CIRL) deletion mutants” J Biol Chem. 1999 274:3590-6. cited by other Missale et al., “Dopamine receptors: from structure to function,” Physiol Rev. 1998 78:189-225 (Review). cited by other Mouledous et al., “Functional inactivation of the nociceptin receptor by alanine substitution of glutamine 286 at the C terminus of transmembrane segment VI: evidence from a site-directed mutagenesis study of the ORL1 receptor transmembrane-binding domain” Mol Pharmacol. 2000 57:495-502. cited by other Olah et al., “The role of receptor structure in determining adenosine receptor activity,” Pharmacol Ther. 2000 85:55-75 (Review). cited by other Orry et al., “Modeling and docking the endothelin G-protein-coupled receptor,” Biophys J. 2000 79:3083-94. cited by other Palczewski et al., “Crystal structure of rhodopsin: A G protein-coupled receptor”, Science 2000 289:739-45. cited by other Sealfon et al., Functional domains of the gonadotropin-releasing hormone receptor, Cell Mol Neurobiol. 1995 15:25-42 (Review). cited by other Shin N et al., Molecular modeling and site-specific mutagenesis of the histamine-binding site of the histamine H4 receptor. Mol Pharmacol. 2002 62:38-47. cited by other Ulloa-Aguirre et al., “Structure-activity relationships of G protein-coupled receptors” Arch Med Res. 1999 30:420-35 (Review). cited by other Yang et al., “Molecular determinants of human melanocortin-4 receptor responsible for antagonist SHU9119 selective activity” J Biol Chem. 2002 277:20328-35. cited by other |
| Primary Examiner: | Ulm, John D |
| Attorney, Agent or Firm: | Keddie, James S. Francis, Carol L. Bozicevic, Field & Francis LLP |
| Accession Number: | edspgr.07776558 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|